AstraZeneca Pharma India gets CDSCO nod for Enhertu in additional breast cancer use

What to watch

• Formal announcement of commercial launch date and India list price for the added indication.
• Any CDSCO, NPPA or other statutory conditions affecting import, sale, labeling or pricing.
• Inclusion or expansion of Enhertu coverage in private insurance, employer health plans or public reimbursement programs.
• Hospital formulary additions and procurement tenders at leading oncology chains.
• Growth in HER2 diagnostic-testing volumes and physician adoption commentary.
• Supply availability, import cadence and distributor inventory disclosures.
• Updated Indian or international breast-cancer treatment guidelines and competing therapy approvals.
• Complete any remaining import, labeling, pricing and commercial-distribution approvals for the new indication.
• Expand engagement with oncologists, pathology laboratories and HER2-testing providers to identify eligible patients.
• Use patient-assistance, insurer discussions and hospital procurement agreements to reduce affordability barriers.
• Scale specialty-distributor inventory, cold-chain planning and infusion-center support ahead of commercial rollout.
• Monitor competitor treatment launches and guideline updates that could affect sequencing of HER2-positive breast cancer therapies.